CoChat
Sign Up
Cited by 261

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity

Gerhard, Danielle M., Wohleb, Eric S., Duman, Ronald S.·2016·Drug Discovery Today
DOI 10.1016/j.drudis.2016.01.016PMC PMC4803609
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.drudis.2016.01.016

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 22 references

Research works printed but not linked: 78

  1. Reddy, 2010, Depression: the disorder and the burden, Indian J. Psychol. Med., 32, 1, 10.4103/0253-7176.70510 · DOI · Paper page
  2. Greenberg, 2015, The economic burden of adults with major depressive disorder in the United States (2005 and 2010), J. Clin. Psychiatry, 76, 155, 10.4088/JCP.14m09298 · DOI · Paper page
  3. Karch, 2012, Surveillance for violent deaths—National Violent Death Reporting System, 16 states, 2009, MMWR Surveill. Summ., 61, 1
  4. Trivedi, 2006, Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice, Am. J. Psychiatry, 163, 28, 10.1176/appi.ajp.163.1.28 · DOI · Paper page
  5. Undurraga, 2012, Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review, Neuropsychopharmacology, 37, 851, 10.1038/npp.2011.306 · DOI · Paper page
  6. Li, 2010, mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists, Science, 329, 959, 10.1126/science.1190287 · DOI · Paper page
  7. Li, 2011, Glutamate N-methyl-d-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure, Biol. Psychiatry, 69, 754, 10.1016/j.biopsych.2010.12.015 · DOI · Paper page
  8. Harrigan, 1999, ECG abnormalities in tricyclic antidepressant ingestion, Am. J. Emerg. Med., 17, 387, 10.1016/S0735-6757(99)90094-3 · DOI
  9. Sharpley, 1995, Effect of pharmacologic treatments on the sleep of depressed patients, Biol. Psychiatry, 37, 85, 10.1016/0006-3223(94)00135-P · DOI
  10. Sussman, 2001, Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials, J. Clin. Psychiatry, 62, 256, 10.4088/JCP.v62n0407 · DOI
  11. Birmes, 2003, Serotonin syndrome: a brief review, CMAJ, 168, 1439
  12. Zorrilla, 2010, Progress in corticotropin-releasing factor-1 antagonist development, Drug Discov. Today, 371, 10.1016/j.drudis.2010.02.011 · DOI
  13. Sullivan, 2000, Genetic epidemiology of major depression: review and meta-analysis, Am. J. Psychiatry, 157, 1552, 10.1176/appi.ajp.157.10.1552 · DOI · Paper page
  14. Walsh, 2002, Placebo response in studies of major depression: variable, substantial, and growing, JAMA, 1840, 10.1001/jama.287.14.1840 · DOI · Paper page
  15. Mayberg, 1997, Limbic-cortical dysregulation: a proposed model of depression, J. Neuropsychiatry Clin. Neurosci., 9, 471, 10.1176/jnp.9.3.471 · DOI · Paper page
  16. Kang, 2012, Decreased expression of synapse-related genes and loss of synapses in major depressive disorder, Nat. Med., 18, 1413, 10.1038/nm.2886 · DOI · Paper page
  17. Treadway, 2015, Illness progression, recent stress, and morphometry of hippocampal subfields and medial prefrontal cortex in major depression, Biol. Psychiatry, 77, 285, 10.1016/j.biopsych.2014.06.018 · DOI · Paper page
  18. Drevets, 2002, Glucose metabolism in the amygdala in depression: relationship to diagnostic subtype and plasma cortisol levels, Pharmacol. Biochem. Behav., 71, 431, 10.1016/S0091-3057(01)00687-6 · DOI · Paper page
  19. Anand, 2005, Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study, Biol. Psychiatry, 57, 1079, 10.1016/j.biopsych.2005.02.021 · DOI · Paper page
  20. Shansky, 2009, Stress-induced dendritic remodeling in the medial prefrontal cortex: effects of circuit, hormones and rest, Brain Res., 1293, 108, 10.1016/j.brainres.2009.03.062 · DOI
  21. Liston, 2006, Stress-induced alterations in prefrontal cortical dendritic morphology predict selective impairments in perceptual attentional set-shifting, J. Neurosci., 26, 7870, 10.1523/JNEUROSCI.1184-06.2006 · DOI · Paper page
  22. Liu, 2008, Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy, Proc. Natl. Acad. Sci. U. S. A., 105, 359, 10.1073/pnas.0706679105 · DOI · Paper page
  23. McEwen, 2012, Stress and anxiety: structural plasticity and epigenetic regulation as a consequence of stress, Neuropharmacology, 62, 3, 10.1016/j.neuropharm.2011.07.014 · DOI · Paper page
  24. Lucassen, 2010, Regulation of adult neurogenesis by stress, sleep disruption, exercise and inflammation: Implications for depression and antidepressant action, Eur. Neuropsychopharmacol., 20, 1, 10.1016/j.euroneuro.2009.08.003 · DOI · Paper page
  25. Gronli, 2006, Chronic mild stress inhibits BDNF protein expression and CREB activation in the dentate gyrus but not in the hippocampus proper, Pharmacol. Biochem. Behav., 85, 842, 10.1016/j.pbb.2006.11.021 · DOI · Paper page
  26. Schmidt, 2010, Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models, Neuropsychopharmacology, 35, 2378, 10.1038/npp.2010.114 · DOI · Paper page
  27. Egan, 2003, The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function, Cell, 112, 257, 10.1016/S0092-8674(03)00035-7 · DOI · Paper page
  28. Bueller, 2006, BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects, Biol. Psychiatry, 59, 812, 10.1016/j.biopsych.2005.09.022 · DOI
  29. Soliman, 2010, A genetic variant BDNF polymorphism alters extinction learning in both mouse and human, Science, 327, 863, 10.1126/science.1181886 · DOI · Paper page
  30. Colzato, 2011, BDNF Val66Met polymorphism is associated with higher anticipatory cortisol stress response, anxiety, and alcohol consumption in healthy adults, Psychoneuroendocrinology, 36, 1562, 10.1016/j.psyneuen.2011.04.010 · DOI
  31. Chen, 2006, Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior, Science, 314, 140, 10.1126/science.1129663 · DOI · Paper page
  32. Liu, 2012, Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex, Biol. Psychiatry, 71, 996, 10.1016/j.biopsych.2011.09.030 · DOI · Paper page
  33. Bath, 2012, BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity, Neuropsychopharmacology, 37, 1297, 10.1038/npp.2011.318 · DOI · Paper page
  34. Duman, 2012, Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents, Trends Neurosci., 35, 47, 10.1016/j.tins.2011.11.004 · DOI · Paper page
  35. Berman, 2000, Antidepressant effects of ketamine in depressed patients, Biol. Psychiatry, 47, 351, 10.1016/S0006-3223(99)00230-9 · DOI · Paper page
  36. Duman, 2014, Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections, Dialogues Clin. Neurosci., 16, 11, 10.31887/DCNS.2014.16.1/rduman · DOI · Paper page
  37. Iadarola, 2015, Ketamine and other N-methyl-d-aspartate receptor antagonists in the treatment of depression: a perspective review, Ther. Adv. Chronic Dis., 6, 97, 10.1177/2040622315579059 · DOI · Paper page
  38. Curran, 2000, Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later, Addiction, 95, 575, 10.1046/j.1360-0443.2000.9545759.x · DOI
  39. Lorrain, 2003, Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268, Neuroscience, 117, 697, 10.1016/S0306-4522(02)00652-8 · DOI
  40. Chowdhury, 2012, (1)H-[(1)(3)C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism, Biol. Psychiatry, 71, 1022, 10.1016/j.biopsych.2011.11.006 · DOI · Paper page
  41. Lepack, 2015, BDNF release is required for the behavioral actions of ketamine, Int. J. Neuropsychopharmacol., 18, 10.1093/ijnp/pyu033 · DOI · Paper page
  42. Hoeffer, 2010, mTOR signaling: at the crossroads of plasticity, memory and disease, Trends Neurosci., 33, 67, 10.1016/j.tins.2009.11.003 · DOI · Paper page
  43. Voleti, 2013, Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses, Biol. Psychiatry, 742, 10.1016/j.biopsych.2013.04.025 · DOI · Paper page
  44. Furey, 2006, Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial, Arch. Gen. Psychiatry, 63, 1121, 10.1001/archpsyc.63.10.1121 · DOI · Paper page
  45. Monyer, 1994, Developmental and regional expression in the rat brain and functional properties of four NMDA receptors, Neuron, 12, 529, 10.1016/0896-6273(94)90210-0 · DOI · Paper page
  46. Zarate, 2013, A randomized trial of a low-trapping nonselective N-methyl-d-aspartate channel blocker in major depression, Biol. Psychiatry, 257, 10.1016/j.biopsych.2012.10.019 · DOI · Paper page
  47. Hellweg, 2012, Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD, Int. J. Geriatr. Psychiatry, 27, 651, 10.1002/gps.2766 · DOI
  48. Mealing, 1999, Differences in degree of trapping of low-affinity uncompetitive N-methyl-d-aspartic acid receptor antagonists with similar kinetics of block, J. Pharmacol. Exp. Ther., 288, 204, 10.1016/S0022-3565(24)37943-1 · DOI
  49. Martin, 2010, Blocking the deadly effects of the NMDA receptor in stroke, Cell, 140, 174, 10.1016/j.cell.2010.01.014 · DOI
  50. Preskorn, 2008, An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder, J. Clin. Psychopharmacol., 28, 631, 10.1097/JCP.0b013e31818a6cea · DOI
  51. Zhang, 2008, A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus, Neuropharmacology, 1238, 10.1016/j.neuropharm.2008.08.018 · DOI
  52. Burgdorf, 2011, The N-methyl-d-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats, Neurobiol. Aging, 32, 698, 10.1016/j.neurobiolaging.2009.04.012 · DOI
  53. Burgdorf, 2013, GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects, Neuropsychopharmacology, 38, 729, 10.1038/npp.2012.246 · DOI · Paper page
  54. Preskorn, 2015, Randomized proof of concept trial of GLYX-13, an N-methyl-d-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent, J. Psychiatr. Pract., 21, 140, 10.1097/01.pra.0000462606.17725.93 · DOI · Paper page
  55. Crane, 1959, Cyloserine as an antidepressant agent, Am. J. Psychiatry, 115, 1025, 10.1176/ajp.115.11.1025 · DOI · Paper page
  56. Heresco-Levy, 2013, A randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression, Int. J. Neuropsychopharmacol., 16, 501, 10.1017/S1461145712000910 · DOI · Paper page
  57. Zanos, 2015, The prodrug 4-chlorokynurenine causes ketamine-like antidepressant effects, but not side effects, by NMDA/GlycineB-site inhibition, J. Pharmacol. Exp. Ther., 355, 76, 10.1124/jpet.115.225664 · DOI
  58. Chaki, 2013, mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants, Neuropharmacology, 66, 40, 10.1016/j.neuropharm.2012.05.022 · DOI
  59. Palucha-Poniewiera, 2012, Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test, Prog. Neuropsychopharmacol. Biol. Psychiatry, 39, 102, 10.1016/j.pnpbp.2012.05.015 · DOI
  60. Hascup, 2010, Rapid microelectrode measurements and the origin and regulation of extracellular glutamate in rat prefrontal cortex, J. Neurochem., 115, 1608, 10.1111/j.1471-4159.2010.07066.x · DOI
  61. Dwyer, 2012, mTOR activation is required for the antidepressant effects of mGluR(2)/(3) blockade, Int. J. Neuropsychopharmacol., 15, 429, 10.1017/S1461145711001702 · DOI · Paper page
  62. Palucha-Poniewiera, 2014, Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the mGlu7 agonist AMN082 in the FST in rats, Neuropharmacology, 82, 59, 10.1016/j.neuropharm.2014.03.001 · DOI
  63. Drevets, 2010, Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial, Biol. Psychiatry, 67, 432, 10.1016/j.biopsych.2009.11.021 · DOI · Paper page
  64. Furey, 2010, Scopolamine produces larger antidepressant and antianxiety effects in women than in men, Neuropsychopharmacology, 35, 2479, 10.1038/npp.2010.131 · DOI · Paper page
  65. Ellis, 2014, Antidepressant treatment history as a predictor of response to scopolamine: clinical implications, J. Affect. Disord., 162, 39, 10.1016/j.jad.2014.03.010 · DOI
  66. Gillin, 1991, The effects of scopolamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group, Biol. Psychiatry, 30, 157, 10.1016/0006-3223(91)90170-Q · DOI
  67. Amar, 2010, Blockade of different muscarinic receptor subtypes changes the equilibrium between excitation and inhibition in rat visual cortex, Neuroscience, 169, 1610, 10.1016/j.neuroscience.2010.06.019 · DOI
  68. Navarria, 2015, Rapid antidepressant actions of scopolamine: role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors, Neurobiol. Dis., 82, 254, 10.1016/j.nbd.2015.06.012 · DOI · Paper page
  69. Witkin, 2014, M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine, J. Pharmacol. Exp. Ther., 448, 10.1124/jpet.114.216804 · DOI
  70. Kramer, 1981, Clinical effects of amitriptyline in adolescent depression. A pilot study, J. Am. Acad. Child Psychiatry, 20, 636, 10.1016/S0002-7138(09)61650-2 · DOI
  71. Fischell, 2015, Rapid antidepressant action and restoration of excitatory synaptic strength after chronic stress by negative modulators of alpha5-containing GABAA receptors, Neuropsychopharmacology, 10.1038/npp.2015.112 · DOI · Paper page
  72. Atack, 2005, In vivo labelling of 5 subunit containing GABAA receptors using the selective radioligand [3H]L655,708, Neuropharmacology, 49, 220, 10.1016/j.neuropharm.2005.03.004 · DOI
  73. Atack, 2006, L655,708 enhances cognition in rats, but is not proconvulsant at a dose selective for 5 containing GABAA receptors, Neuropharmacology, 51, 1023, 10.1016/j.neuropharm.2006.04.018 · DOI
  74. Wang, 2013, Brain damages in ketamine addicts as revealed by magnetic resonance imaging, Front. Neuroanat., 23
  75. Lapidus, 2014, A randomized controlled trial of intranasal ketamine in major depressive disorder, Biol. Psychiatry, 76, 970, 10.1016/j.biopsych.2014.03.026 · DOI · Paper page
  76. aan het Rot, 2010, Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression, Biol. Psychiatry, 67, 139, 10.1016/j.biopsych.2009.08.038 · DOI · Paper page
  77. Smiley, 1993, Heterogeneous targets of dopamine synapses in monkey prefrontal cortex demonstrated by serial section electron microscopy: a laminar analysis using the silver-enhanced diaminobenzidine sulfide (SEDS) immunolabeling technique, Cereb. Cortex, 3, 223, 10.1093/cercor/3.3.223 · DOI · Paper page
  78. Wang, 2009, Cell type-specific development of NMDA receptors in the interneurons of rat prefrontal cortex, Neuropsychopharmacology, 2028, 10.1038/npp.2009.20 · DOI

Cited by

Sorted by citations

See all 261

Metadata

Authors
Gerhard, D. M., Wohleb, E. S., & Duman, R. S.
Venue
Drug Discovery Today
Publisher
Elsevier BV
Published
2016-03
Volume
21
Issue
3
Pages
454-464
ISSN
1359-6446
DOI
10.1016/j.drudis.2016.01.016
PMC
PMC4803609
Cited by
261
References
22
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review